Systolic Heart Failure
At the Forefront of Care for Patients with Worsening Heart Failure: New and Emerging Treatment Options
Supported by an independent medical educational grant from Merck.
Bias against higher recommended drug doses for HF may be present
The uptitration of drugs used to treat patients with chronic systolic HF was more likely to be stopped as the dosage became further away from the recommendation dose, especially with higher recommended dosages compared with lower recommended dosages, according to a brief research report published in the Annals of Internal Medicine.
Novel percutaneous LV repair system shows promise in systolic HF
SAN FRANCISCO — Early clinical data suggest that an investigational percutaneous device designed to directly repair the left ventricle is feasible and safe in patients with HF and functional mitral regurgitation. Data on the first 31 patients enrolled in the CorCinch FMR early feasibility study who were treated with the AccuCinch ventricular repair system at U.S. centers through July were presented at TCT 2019.